Comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 vs 14q11 2 Microduplication Syndrome C4749855
Clinical comparison between 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial and 14q11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
A partial form of enzyme deficiency affecting hormone production. Symptoms vary but may include hormonal imbalances and elevated blood pressure. Treatment usually involves hormone replacement and regular medical follow-up.
14q11 2 Microduplication Syndrome C4749855
A rare genetic condition involving a small extra piece of chromosome 14. Features vary and may include developmental delays. Management focuses on supportive therapies and monitoring.
6 comparison axes
Onset
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Variable
14q11 2 Microduplication Syndrome C4749855
0-5
Onset patterns differ
Severity
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
severe
14q11 2 Microduplication Syndrome C4749855
moderate
Different severity levels
Chronic
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
Chronic
14q11 2 Microduplication Syndrome C4749855
Chronic
Differing course
Communicable
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
No
14q11 2 Microduplication Syndrome C4749855
No
Different transmission
Body System
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
14q11 2 Microduplication Syndrome C4749855
congenital
Same/different system
Category
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
endocrine
14q11 2 Microduplication Syndrome C4749855
genetic
Different category
Bottom line
17-alpha-hydroxylase-17-20-lyase-deficiency-combined-partial-C4017190 and 14q11-2-microduplication-syndrome-C4749855 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | 14q11 2 Microduplication Syndrome C4749855 | Discriminating power |
|---|---|---|---|
| Blood pressure | Hypertension may occur from mineralocorticoid imbalance; not universal. | Hypertension is not an established core feature in the supplied description. | Moderate |
| Development | Developmental delay is not described as a defining feature. | Developmental delay may occur, with variable severity. | Moderate |
| Sexual development | Hormone imbalance may affect puberty or sex-steroid production; findings vary. | Atypical sexual development is not established from the supplied source. | Moderate |
When to favor each condition
Choose 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 when
Hypertension with suspected steroid hormone imbalance
The endocrine description supports evaluation for partial enzyme deficiency.
Moderate
Abnormal steroid profile needing specialist review
An abnormal result is not itself a diagnosis and requires endocrine interpretation.
High
Need for hormone replacement planning
Management commonly includes replacement and follow-up, without a fixed regimen here.
Moderate
Choose 14q11 2 Microduplication Syndrome C4749855 when
Early childhood developmental concerns
Reported onset is typically ages 0–5 and features may include delay.
Moderate
Suspected chromosomal copy-number change
The condition is defined by extra 14q11.2 material, confirmed genetically.
High
Need for supportive developmental care
Management emphasizes therapies and monitoring rather than hormone replacement.
Moderate
How key tests differ
| Test | 17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190 | 14q11 2 Microduplication Syndrome C4749855 | Interpretation |
|---|---|---|---|
| Steroid hormone profile | May show enzyme-related hormone imbalance; exact cutoffs are not established here. | No characteristic steroid abnormality is established. | Abnormal results require clinician correlation and do not alone confirm diagnosis. |
| Chromosomal microarray | Not expected to identify this enzyme deficiency. | May detect a 14q11.2 microduplication when present. | Genetic confirmation distinguishes the chromosomal condition. |
| Blood pressure monitoring | May reveal hypertension requiring medical follow-up. | No specific blood-pressure pattern is established. | Findings guide care but are not diagnostic by themselves. |
Prognosis comparison
17 Alpha Hydroxylase 17 20 Lyase Deficiency Combined Partial C4017190
- Outcome
- Chronic and potentially severe, but individual outcome is not established.
- Factors
- Hormone balance, blood pressure, and adherence to follow-up may matter.
14q11 2 Microduplication Syndrome C4749855
- Outcome
- Chronic and generally described as moderate, with variable development.
- Factors
- Extent of duplication and developmental support may influence function.
Time frame: Long-term; onset may be variable or in early childhood.
Prognosis cannot be individualized from these sparse source data.
Complications comparison
| Complication | Presentation |
|---|---|
| Hypertension-related effects | Possible if blood pressure remains elevated. Not established from the supplied description. Risk and outcomes vary; specialist monitoring is appropriate. |
| Developmental impairment | Not described as characteristic. Developmental delay may affect learning or function to varying degrees. Severity is not predictable from the source data. |
| Treatment-related burden | Long-term hormone follow-up may be needed. Ongoing therapy and developmental monitoring may be needed. Specific complications are not established here. |
Patient education highlights
- HighDifferent causes
One is a partial hormone-enzyme problem; the other is a rare chromosomal duplication.
- HighVariable features
Symptoms and severity differ between people, so individual assessment is essential.
- MediumFollow-up
Endocrine care or supportive developmental care should be guided by the confirmed diagnosis.